Evidence map›Paper›PMID 37435061›Full record

ArticleFrontiers in immunology2023

AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation.

Matteo Caforio, Nicola Tumino, Cristina Sorino, Isabella Manni, Stefano Di Giovenale, Giulia Piaggio, Simona Iezzi, Georgios Strimpakos, Elisabetta Mattei, Lorenzo Moretta and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 69% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Matteo CaforioDepartment of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Nicola TuminoImmunology Research Area, Innate Lymphoid Cells Unit, Bambino Gesù Children's Hospital Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Cristina SorinoStabilimento Allevamento Fornitore e Utilizzatore (SAFU) Laboratory, Department of Research, Advanced Diagnostic, Technological Innovation, Regina Elena National Cancer Institute Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Isabella ManniStabilimento Allevamento Fornitore e Utilizzatore (SAFU) Laboratory, Department of Research, Advanced Diagnostic, Technological Innovation, Regina Elena National Cancer Institute Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Stefano Di GiovenaleStabilimento Allevamento Fornitore e Utilizzatore (SAFU) Laboratory, Department of Research, Advanced Diagnostic, Technological Innovation, Regina Elena National Cancer Institute Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Giulia PiaggioStabilimento Allevamento Fornitore e Utilizzatore (SAFU) Laboratory, Department of Research, Advanced Diagnostic, Technological Innovation, Regina Elena National Cancer Institute Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Simona IezziStabilimento Allevamento Fornitore e Utilizzatore (SAFU) Laboratory, Department of Research, Advanced Diagnostic, Technological Innovation, Regina Elena National Cancer Institute Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Georgios StrimpakosNational Research Council (CNR), Institute of Biochemistry and Cell Biology, Monterotondo, Rome, Italy.
Elisabetta MatteiConsiglio Nazionale delle Ricerche (CNR)-Institute of Cell Biology and Neurobiology, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy.
Lorenzo MorettaTumor Immunology Unit , Children Hospital Bambino Gesù, RomaLM, Rome, Italy.
M FanciulliStabilimento Allevamento Fornitore e Utilizzatore (SAFU) Laboratory, Department of Research, Advanced Diagnostic, Technological Innovation, Regina Elena National Cancer Institute Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Paola VaccaImmunology Research Area, Innate Lymphoid Cells Unit, Bambino Gesù Children's Hospital Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Franco LocatelliDepartment of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Valentina FolgieroDepartment of Pediatric Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITBambino Gesù Children's Hospital · ITFondazione Santa Lucia · ITNational Research Council · ITUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: AATF/Che-1 over-expression in different tumors is well known and its effect on tumorigenicity is mainly due to its central role demonstrated in the oncogenic pathways of solid tumors, where it controls proliferation and viability. The effect exerted by tumors overexpressing Che-1 on the immune response has not yet been investigated. Methods: Starting from ChIP-sequencing data we confirmed Che-1 enrichment on Nectin-1 promoter. Several co-cultures experiments between NK-cells and tumor cells transduced by lentiviral vectors carrying Che-1-interfering sequence, analyzed by flow-cytometry have allowed a detailed characterization of NK receptors and tumor ligands expression. Results: Here, we show that Che-1 is able to modulate the expression of Nectin-1 ligand at the transcriptional level, leading to the impairment of killing activity of NK-cells. Nectin-1 down-modulation induces a modification in NK-cell ligands expression able to interact with activating receptors and to stimulate NK-cell function. In addition, NK-cells from Che-1 transgenic mice, confirming a reduced expression of activating receptors, exhibit impaired activation and a preferential immature status. Discussion: The critical equilibrium between NK-cell ligand expression on tumor cells and the interaction with NK cell receptors is affected by Che-1 over-expression and partially restored by Che-1 interference. The evidence of a new role for Che-1 as regulator of anti-tumor immunity supports the necessity to develop approaches able to target this molecule which shows a dual tumorigenic function as cancer promoter and immune response modulator.

Indexed as

Carrier ProteinsNeoplasmsAnimalsApoptosis Regulatory ProteinsLigandsMiceMice, TransgenicNectinsNuclear ProteinsRNA Polymerase IIAatf protein, mouseApoptosis Regulatory ProteinsCarrier ProteinsLigandsNectinsNuclear ProteinsRNA Polymerase IIChe-1immune responseNectin 1NK cellsNK killing activity

Identifiers

PMID37435061
PMCPMC10332273
OpenAlexW4382139310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.